Cantor Fitzgerald Investment Advisors L.P. raised its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 6.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 289,715 shares of the biopharmaceutical company's stock after purchasing an additional 18,267 shares

Great dividend payers can support and raise their payouts through the years. VICI Properties is a leading REIT with a vast portfolio of experience-oriented properties.

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.

AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs.

Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status.

Diversified Trust Co increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 56.0% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 101,051 shares of the biopharmaceutical company's stock after purchasing an additional 36,288 shares during the quarter. Diversified Trust Co's

Abacus FCF Advisors LLC raised its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 2.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 376,150 shares of the biopharmaceutical company's stock after purchasing an additional 10,740 shares during the quarter.

Valley National Advisers Inc. cut its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 82.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,891 shares of the biopharmaceutical company's stock after selling 28,312 shares during the